Primary cutaneous peripheral T-cell lymphoma not otherwise specified

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:86885C84.4
Who is this for?
Show terms as
4FDA treatments1Active trials7Specialists8Treatment centers3Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

Orphanet ↗NORD ↗

FDA & Trial Timeline

4 events
Feb 2026SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma

The First Affiliated Hospital with Nanjing Medical University — PHASE2

TrialNOT YET RECRUITING
Apr 2023A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

The First Affiliated Hospital with Nanjing Medical University

TrialRECRUITING
Jul 2014

Beleodaq: FDA approved

Treatment of patients with relapsed or refractory peripheral T-cell lymphoma

FDAcompleted
Aug 2011

Adcetris: FDA approved

The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

4 available

POLIVY

POLATUZUMAB VEDOTIN· Genentech, Inc.
in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL),

in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater

Folotyn

pralatrexate· Acrotech Biopharma LLCAccelerated Approval

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)

Lymphir

denileukin diftitox-cxdl· Citius Oncology, Inc.■ Boxed Warning

LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy

Beleodaq

Belinostat· Acrotech Biopharma LLCOrphan Drug

Treatment of patients with relapsed or refractory peripheral T-cell lymphoma

Clinical Trials

1 recruitingView all trials with filters →
Other1 trial
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.
Actively Recruiting
· Sites: Nanjing, Jiangsu · Age: 1899 yrs

Specialists

7 foundView all specialists →
TM
Thomas E. Witzig, MD
ROCHESTER, MN
Specialist
PI on 9 active trials
SM
Swaminathan P Iyer, MD
HOUSTON, TX
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

3 resources
POLIVY(POLATUZUMAB VEDOTIN)Genentech, Inc.
Folotyn(pralatrexate)Acrotech Biopharma LLC
Beleodaq(Belinostat)Acrotech Biopharma LLC

Travel Grants

No travel grants are currently matched to Primary cutaneous peripheral T-cell lymphoma not otherwise specified.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Primary cutaneous peripheral T-cell lymphoma not otherwise specifiedForum →

No community posts yet. Be the first to share your experience with Primary cutaneous peripheral T-cell lymphoma not otherwise specified.

Start the conversation →

Latest news about Primary cutaneous peripheral T-cell lymphoma not otherwise specified

1 articles
NewsFDA
FDA Approves POLIVY
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) received FDA approval.
See all news about Primary cutaneous peripheral T-cell lymphoma not otherwise specified

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Primary cutaneous peripheral T-cell lymphoma not otherwise specified

Are there clinical trials for Primary cutaneous peripheral T-cell lymphoma not otherwise specified?

Yes — 1 recruiting clinical trial is currently listed for Primary cutaneous peripheral T-cell lymphoma not otherwise specified on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Primary cutaneous peripheral T-cell lymphoma not otherwise specified?

7 specialists and care centers treating Primary cutaneous peripheral T-cell lymphoma not otherwise specified are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Primary cutaneous peripheral T-cell lymphoma not otherwise specified?

4 patient support programs are currently tracked on UniteRare for Primary cutaneous peripheral T-cell lymphoma not otherwise specified. See the treatments and support programs sections for copay assistance, eligibility, and contact details.